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Renovascular parathyroid hormone-related protein in spontane-
ously hypertensive rats: Dilator or trophic factor? Parathyroid
hormone-related protein (PTHrP) is expressed throughout the
renovascular system, and it dilates renal vessels, increases renal
blood flow and glomerular filtration rate, and stimulates renin
release. Mechanical forces and experimental hypertension have
been shown to stimulate PTHrP expression in smooth muscles,
suggesting a negative feedback control of vascular tone by PTHrP
in hypertension. In this study, we compared the impact of a
PTHrP receptor antagonist, PTHrP (7-34), and a PTHrP receptor
agonist, PTHrP (1-36), on the vascular resistance of perfused
kidneys isolated from spontaneously hypertensive rats (SHR) and
Wistar Kyoto rats (WKY). Endogenous PTHrP appears not to act
as a renal vasodilator in either WKY or SHR. However, the
vasodilation following infused PTHrP (1-36) is blunted markedly
in SHR, possibly due to desensitization or down-regulation of
PTH/PTHrP receptors. Negative feedback control of vascular
tone by PTHrP in SHR thus appears unlikely. The results raise the
question of whether endogenous renovascular PTHrP behaves
rather as a growth factor than as a vasodilator.
Cross-transplantation experiments provide convincing
evidence for the kidney’s pivotal role in the development of
hypertension. Thus, hypertension develops in normotensive
rats following a kidney transplant from genetically sponta-
neously hypertensive rats (SHR) [1]. Differences in renal
hemodynamics in rats (SHR) compared with normotensive
control Wistar Kyoto (WKY) rats include increased vascu-
lar resistance (RVR), enhanced tubuloglomerular feed-
back, an abnormal glomerular pressure-filtration curve, an
exaggerated vascular response to vasoconstrictors, reduced
negative feedback control of dilator factors, preglomerular
vascular hypertrophy/hyperplasia, and exaggerated growth
response to mitogens [2, 3].
Parathyroid hormone-related protein (PTHrP) was puri-
fied and cloned 10 years ago from tumors as the PTH-like
hypercalcemic factor of humoral hypercalcemia of malig-
nancy [4]. It is now clear that the term “PTHrP” is
misleading, as the protein differs markedly from PTH:
First, the PTH-like effects of PTHrP (1-141) on bone and
kidney are confined to its (1-36) N-terminal part. Second,
with the exception of a small N-terminal region, PTHrP
structure differs markedly from PTH. Third, although
structurally related to the PTH gene, PTHrP is the product
of a separate gene. Fourth, unlike PTH, PTHrP is a
paracrine factor expressed throughout the body, and finally,
most of the functions of PTHrP are unrelated to those of
PTH. In fact, PTHrP is now considered as a prohormone,
comprising a family of distinct peptide hormones arising
from posttranslational endoproteolytic cleavage of the ini-
tial PTHrP translation product. Mature N-terminal, midre-
gion, and C-terminal secretory forms of PTHrP are thus
generated, each with its own physiological functions.
PTHrP (1-36) is not only a PTH-like calciotropic hormone
but also a potent myorelaxant. Importantly, PTHrP is a
developmental regulatory molecule and a cytokine-like
growth factor and has less in common functionally with
PTH than with a number of developmental factors. It has
already been suggested that a more appropriate name for
PTHrP should emphasize this aspect of its physiological
roles [5]. Reviews detail the progress made with respect to
developmental and physiological roles of PTHrP since its
purification and structural identification [5, 6].
Parathyroid hormone-related protein is expressed
throughout the cardiovascular system, and N-terminal frag-
ments of PTHrP are inotropic and chronotropic in the
heart and vasodilate vessels [5, 6]. PTHrP (1-36) also
relaxes bladder, uterus, and gastrointestinal tract [5]. In a
recent assessment of the systemic and local hemodynamic
effects of PTHrP (1-34) in healthy volunteers, the renal
vasculature was the primary cardiovascular target of i.v.
PTHrP (1-34) [7]. PTHrP (1-36) binds to PTH receptors in
renal arterioles [8], increases renal blood flow and glomer-
ular filtration rate in the anesthetized rat [9, 10], and
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vasodilates the isolated perfused rat kidney [11]. Together
with its direct renin stimulatory effects [12] and its presence
throughout the juxtaglomerular apparatus, including the
macula densa [13], these studies strongly suggest that
PTHrP (1-36) is an as yet unidentified regulator of renal
hemodynamics.
Mechanical stretch or distention up-regulates PTHrP in
hollow organs, heart, and vessels within two hours [14].
Overproduced PTHrP may, in turn, help to adapt wall
compliance to luminal filling or pressure increase. The
vasodilator effect of PTHrP (1-36) might also balance
vasoconstrictor effect and exert a negative feedback control
of vascular tone. For example, constrictors angiotensin II
(Ang II) [15] or endothelin-1 [16] up-regulate dilatory
PTHrP in vascular smooth muscle cells (VSMCs), in turn
stimulating renin secretion. Consistent with these findings,
preliminary studies indicate that PTHrP expression might
be increased in the aorta of SHR [14]. These, together with
our previous observation on the abundant expression of
PTHrP in the renal vasculature [13], suggest a negative
feedback control of vascular tone by PTHrP in hyperten-
sion. We therefore explored the dilatory properties of
endogenous and exogenous PTHrP in the renal vasculature
of SHR and WKY in vitro.
METHODS
Preparation of the isolated rat kidney
Male 12-week-old SHR or WKY (Iffa Credo, l’Arbresle,
France) were anesthetized by i.p. sodium pentobarbital (65
mg/kg21). The right kidney was isolated and perfused
extracorporally as described previously [12, 17]. Briefly,
after injection of heparin (1000 U) into the left femoral
artery, the right kidney was perfused in an open, nonrecir-
culating circuit through the superior mesenteric artery.
Perfusion pressure was continuously monitored with a
pressure transducer (Statham P23Db; Statham Laborato-
ries Inc., Hato Rey, Puerto Rico) through the infrarenal
aorta. The perfusion medium (a Krebs-Ringer-gelatine-
lactate solution, Plasmion; Rhoˆne-Poulenc Rorer, Antony,
France) was maintained at 37°C, filtered continuously
through a 1.2 mm sieve, and gassed with 95% O2/5% CO2.
pH was 7.39 to 7.44 in the prewarmed, preoxygenated
medium.
Vasodilatory effect of exogenous parathyroid hormone-
related protein (1-36)
In these experiments, perfusion flow was adjusted in a
60-minute equilibration period to achieve a pressure base-
line of 80 mm Hg. Flow was kept constant thereafter.
Phenylephrine (PE) was injected over 15-second periods
every two minutes to induce repetitive and transient vaso-
constrictions of about 35 to 40 mm Hg. The vasodilatory
responses to PTHrP (1-36; Bachem, Bubbendorf, Switzer-
land) were assessed as the ability of continuously infused
PTHrP (1-36; 3 or 30 nM) to attenuate PE-induced vaso-
constriction.
Effect of parathyroid hormone/parathyroid hormone-
related protein receptor antagonist on renal vascular
resistance
In further experiments, perfusion was adjusted during a
30-minute equilibration period to achieve an 80 mm Hg
baseline pressure, as mentioned earlier here. This pressure
was then kept constant by computerized servocontrol of the
perfusion pump. After equilibration, kidneys were perfused
with or without 40 nM PTHrP (7-34), a PTH/PTHrP
receptor antagonist [18], in the medium. RVR was mea-
sured after the initial equilibration period and after 30
minutes of further perfusion with or without PTHrP (7-34).
Calculations
Renal vascular resistance is expressed per 1 g kidney
weight (in mm Hg min/g/ml). The left kidney weight was
used for calculation. All pressure and RVR values were
expressed as means 6 SE. Analysis of variance followed by
the Student-Newman-Keul’s test was performed on the
absolute values of the various parameters. Differences were
considered significant when P , 0.05.
RESULTS AND DISCUSSION
Phenylephrine concentrations required to induce a sim-
ilar preconstriction (37.2 6 1.5 and 36.9 6 1.4 mm Hg)
were 7.9 6 1.3 and 3.5 6 0.5 mM (P , 0.05, N 5 9 and 7)
in WKY and SHR, respectively. PTHrP (1-36) at 3 and 30
nM decreased the PE-induced vasoconstriction in both
strains (Fig. 1). The higher concentration reduced the
PE-induced vasoconstriction in WKY by 70%. In SHR, the
lower PTHrP (1-36) concentration maximally decreased
the PE-induced vasoconstriction by 30%.
Endogenous vasoactive PTHrP is believed to be overpro-
duced in SHR and may thus be responsible for the lower
response to exogenous PTHrP in SHR. We therefore
measured RVR in kidneys perfused for 30 minutes without
or with 40 nM PTHrP (7-34), a PTH/PTHrP receptor
antagonist. Although RVR in SHR was significantly higher
than in WKY, it did not change in either WKY (6.9 6 0.5,
N 5 9 vs. 7.2 6 0.6, N 5 5) or SHR (9.6 6 0.9, N 5 7 vs.
9.3 6 0.7, N 5 3).
These results suggest that PTHrP is not an endogenous
renal vasodilator in either WKY or SHR. First, although
N-terminal-truncated PTH and PTHrP potently inhibit
PTHrP-induced renal vasodilation [10, 11] and PTHrP-
stimulated adenylyl cyclase [11] in renal arterioles, in the
present study PTHrP (7-34) had no effect on RVR of in
vitro perfused kidneys from WKY or SHR. This is consis-
tent with a previous study in the anesthetized rat indicating
that intrarenally infused PTHrP (7-34) has no effect on
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renal blood flow [10]. Second, vasodilation following exog-
enous PTHrP (1-36) is markedly decreased in SHR versus
WKY.
Parathyroid hormone-related protein is expressed
throughout the glomerulovasculature, including the glo-
merular epithelial cells, the afferent arteriolar vascular
wall, and the macula densa [13]. Moreover, PTHrP is
believed to be up-regulated in the aorta of SHR [14]. In
experimental hypertension induced by Ang II infusion and
salt loading, PTHrP is also up-regulated in the aorta [19].
However, in this latter study, it is not clear whether PTHrP
is induced through the direct action of Ang II or in
response to wall distention resulting from hypertension. It
is thus reasonable to anticipate that PTHrP is up-regulated
in the renovascular system of SHR as well. If so, then the
blunted vasodilation of PTHrP in SHR could be due to
desensitization or down-regulation of renovascular PTH/
PTHrP receptors. The reduced PTH/PTHrP receptor den-
sity in renal cortical membranes from SHR strongly sup-
ports this hypothesis [20]. Moreover, PTH/PTHrP receptor
down-regulation is frequently associated with PTHrP up-
regulation in vascular systems. Thus, Ang II induces PTHrP
mRNA in VSMCs but also desensitizes the cAMP response
and down-regulates the PTH/PTHrP receptor mRNA
within one hour [21]. PTHrP is also up-regulated markedly
during the course of arterial sclerosis and PTHrP increases
in rat carotid and human coronary artery during neointimal
formation following angioplasty, coincident with down-
regulation of PTH/PTHrP receptor mRNA expression [22].
Nevertheless, further studies must examine specifically
whether PTHrP is up-regulated and PTH/PTHrP receptors
are down-regulated in the renal vasculature of SHR.
These findings raise the possibility that endogenous
PTHrP might play nonvasoactive roles in the renal vascu-
lature. For instance, PTHrP regulates VSMC proliferation.
PTHrP (1-36) is an autocrine/paracrine inhibitor of VSMC
proliferation, whereas as yet unknown species of PTHrP
may have so called “intracrine” proliferative effects [23].
Consistent with this, the PTHrP precursor contains multi-
basic clusters at the 88 to 106 region homologous to the
nucleolar targeting signal consensus sequences found in
several human retroviral transcription factors and fibro-
blast growth factors and responsible for targeting PTHrP to
the nucleolus and proliferative functions. Thus, in cultured
keratinocytes [24, 25], nucleolar targeting of PTHrP occurs
and may explain the directionally opposite effects on
proliferation compared with the addition of PTHrP to the
medium. In chondrocytes, PTHrP also has important ef-
fects on apoptotic cell death, most likely related to its
intracrine action [26]. In this important study, targeting is
mediated by a nuclear sequence in the 88 to 106 region.
Moreover, this region can direct chimeric, cytosolic protein
to the nucleus [26]. If this is so in VSMCs, then the question
of how and under what circumstances the nascent peptide
leaves the classic endoplasmic secretory pathway and trans-
locates to the nucleus must be elucidated.
Together, the results reported here do not support a
negative feedback control by PTHrP of renovascular tone
in either normotensive or hypertensive rats. Whether en-
dogenous renovascular PTHrP is mainly a factor regulating
vascular wall modeling under various pathophysiological
circumstances awaits further study.
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APPENDIX
Abbreviations used in this article are: Ang II, angiotensin II; PE,
phenylephrine; PTHrP, parathyroid hormone-related peptide; RVR, renal
Fig. 1. Parathyroid hormone-related peptide
(PTHrP; 1-36)-induced vasodilation in
constant-flow perfused kidney isolated from
Wistar Kyoto (WKY) rats (M, N 5 9) and SHR
(f, N 5 7). The left ordinate shows the
absolute value of the phenylephrine (PE)-
induced vasoconstriction in absence or presence
of 3 or 30 nM PTHrP (1-36). The right ordinate
shows the same results expressed as a
percentage of the PTHrP (1-36)-induced
vasodilation. *P , 0.05 versus vasoconstriction
induced by PE in absence of PTHrP (1-36),
#P , 0.05 versus WKY
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vascular resistance; SHR, spontaneously hypertensive rats; VSMCs, vas-
cular smooth muscle cells; WKY, Wistar Kyoto rats.
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